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ABSTRACT Prostaglandin H2 synthase (PGHS) synthesizes PGH2, a prostaglandin precursor, from arachidonic acid and
was the ﬁrst monotopic enzyme to have its structure experimentally determined. Both isozymes of PGHS are inhibited by
nonsteroidal antiinﬂammatory drugs, an important class of drugs that are the primary means of relieving pain and inﬂammation.
Selectively inhibiting the second isozyme, PGHS-2, minimizes the gastrointestinal side-effects. This had been achieved by the
new PGHS-2 selective NSAIDs (i.e., COX-2 inhibitors) but it has been recently suggested that they suffer from additional side-
effects. The design of these drugs only made use of static structures from x-ray crystallographic experiments. Investigating the
dynamics of both PGHS-1 and PGHS-2 using classical molecular dynamics is expected to generate new insight into the
differences in behavior between the isozymes, and therefore may allow improved PGHS-2 selective inhibitors to be designed.
We describe a molecular dynamics protocol that integrates PGHS monomers into phospholipid bilayers, thereby producing in
silico atomistic models of the PGHS system. Our protocol exploits the vacuum created beneath the protein when several lipids
are removed from the top leaﬂet of the bilayer. The protein integrates into the bilayer during the ﬁrst 5 ns in a repeatable
process. The integrated PGHS monomer is stable and forms multiple hydrogen bonds between the phosphate groups of the
lipids and conserved basic residues (Arg, Lys) on the protein. These interactions stabilize the system and are similar to inter-
actions observed for transmembrane proteins.
INTRODUCTION
Monotopic proteins are integral membrane proteins but, un-
like transmembrane proteins, their polypeptide chains do not
cross the phospholipid bilayer (1). To date only four monotopic
proteins have had their structures experimentally determined;
prostaglandin H2 synthase (PGHS) (2), squalene-hopene
cyclase (3), monoamine oxidase (4), and fatty acid amide hy-
drolase (5). There is tremendous academic and industrial in-
terest in monotopic proteins; for example, all four enzymes
for which structures exist are important pharmaceutical drug
targets.
PGHS (EC No. 1.14.99.1) catalyses the conversion of
arachidonic acid, a 20-carbon fatty acid, to prostaglandin H2
(PGH2), the precursor of the prostaglandin class of local
hormones. The reaction proceeds within PGHS in two steps
at spatially distinct active sites: arachidonate and two mole-
cules of oxygen are reacted together at the cyclooxygenase
(COX) site to form prostaglandin G2 (PGG2), which is then
reduced to PGH2 at the peroxidase site (6). PGHS is often
called COX due to its cyclooxygenase function. We will not
discuss the structure, biochemistry, and inhibition of PGHS
in detail as there are many excellent reviews (7–11).
PGHS is interesting because not only is it a monotopic
protein but also two genes encode similar PGHS enzymes
(11). Additional splice variants of the PGHS-1 isozyme have
been proposed, potentially increasing this number (12).
PGHS-1 is constitutively expressed and synthesizes prosta-
glandins involved in homeostasis, for example maintaining
the mucosal lining of the stomach (13). PGHS-2 is induced
and rat models have demonstrated that this enzyme is in-
volved in local pain and inﬂammation responses (14,15).
The PGHS enzymes have also been implicated in other
human pathologies, for example in various cancers (10).
Nonsteroidal antiinﬂammatory drugs (NSAIDs), such as
aspirin, ibuprofen, and ﬂurbiprofen, bind within the cyclo-
oxygenase active site, limiting the production of PGH2 and
therefore inhibiting the action of the enzyme. The ulcero-
genic and renal side-effects of NSAIDs are caused by
inhibition of PGHS-1 and the majority of classical NSAIDs
(e.g., aspirin and ibuprofen) are either not selective or inhibit
PGHS-1. Consequently there has been a tremendous effort in
the last decade to design an NSAID that is speciﬁc to PGHS-
2 and therefore has reduced side-effects, while maintaining
the desired analgesic and antiinﬂammatory actions. This
culminated in 1999 in the introduction of several so-called
COX-2 inhibitors, most notably celecoxib (Celebrex, Pﬁzer)
and rofecoxib (Vioxx, Merck). Interest in these important
clinical inhibitors has increased recently due to the with-
drawal of rofecoxib in 2004 by its manufacturer because of a
higher incidence of myocardial infarction during an extended
clinical trial. The mechanism of this side-effect is not known.
A recent population study by Hippisley-Cox and Coupland
(16) suggested that other NSAIDs, including ibuprofen,
may also suffer from the same side-effect, albeit to differing
degrees.
Designing an isozyme-speciﬁc inhibitor is an extremely
difﬁcult task because the isozymes are structurally very similar.
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For example, the sequence similarity between PGHS-1 and
PGHS-2 is 60–65% within the same species (10) and the root
mean-square deviation (RMSD)over theCa atoms is 0.9–1.0 A˚
when comparing the different sheep PGHS-1 and mouse
PGHS-2 x-ray crystal structures. The PGHS active site, as
deﬁned by those residues in close contact with the bound
substrate, is highly conserved with only a single amino acid
difference (I523V) between isozymes. We will follow the
convention of using the amino acid numbering of sheepPGHS-
1. The less bulky side chain of valine compared to isoleucine
permits ligands to access an additional side-pocket seen in the
x-ray crystallographic structures of PGHS-2 (17). TheCOX-2
inhibitors exploit this pocket and mutagenesis experiments
have demonstrated that this mutation is important in produc-
ing the selectivity of these new inhibitors (18–20).
The x-ray crystallographic structure of a monotopic pro-
tein is a static snapshot of the protein at cryogenic tem-
peratures and contains little dynamical information. Kinetic
studies have revealed that the dynamics of PGHS is important
for its inhibition by NSAIDs (21,22). Studying the dynamics
of PGHS-1 and PGHS-2 is likely to lead to additional insight
beyond that gained when comparing static x-ray crystallog-
raphy structures and therefore could inform future drug
design. This study is the ﬁrst step toward analyzing such
dynamical differences between PGHS-1 and -2.
We use large-scale classical molecular dynamics (MD) to
study the dynamics of this system. MD is constrained by the
short timescales, typically tens of nanoseconds, that it can ac-
cess relative to those of more general biological interest, but
it allows insight to be gained into the dynamics (and there-
fore behavior) of these proteins that is not possible by ex-
periment. Hypotheses may then be generated which can be
tested experimentally in an iterative process.
It is not known what aspects of the system will be important
in determining the dynamical differences (if any) between the
PGHS isozymes and it is therefore prudent to include a
phospholipid bilayer, since this forms many interactions with
PGHS. Unfortunately, it is difﬁcult to build atomistic mod-
els of monotopic proteins anchored to a membrane as, unlike
transmembrane proteins, there are no clear transmembrane
units (e.g., a-helices or a b-barrel) with which to position the
protein relative to the membrane. The purpose of this article is
to outline a protocol for integrating a PGHS monomer into a
phospholipid bilayer. We expect a PGHS dimer to integrate in
the same way as the monomer. We shall present evidence to
demonstrate that the protein is correctly inserted before
making some concluding remarks.
METHOD
In this section we describe the structure of PGHS, deﬁne our protocol for
integrating a PGHS monomer with a phospholipid bilayer, and provide de-
tails about the MD algorithm used.
Structure of prostaglandin H2 synthase
PGHS is situated on both the luminal side of the endoplasmic reticulum and
on the nuclear membrane (23,24). X-ray crystallography indicates that the
protein is a dimer, is mainly a-helical, and comprises 550–553 residues per
monomer. Each monomer has three domains (see Fig. 1): an epidermal-
growth factor (EGF)-like domain (residues 33–72), the catalytic domain
(residues 117–586), and the membrane-binding domain (MBD, residues
73–116). A PGHS monomer is not biologically active, and therefore, if we
drew any conclusions from the simulations of the monomer about the
dynamical differences between the two isozymes, we would ﬁrst have to ﬁrst
establish that the structure and dynamics of an integrated PGHS monomer
are similar to that of an integrated PGHS dimer.
The MBD is composed of four a-helices, A, B, C, and D, the ﬁrst three
roughly forming three sides of a square with D connecting this motif to the
catalytic domain. Picot et al. (2) hypothesized that these three short helices
lie in the plane of the membrane near one interface, form numerous inter-
actions with the top leaﬂet of the bilayer, and thereby bind the protein to
the membrane. This was supported by surface plots of the hydrophobicity
FIGURE 1 The secondary and tertiary structure of ovine sp. prostaglandin H2 synthase-1 dimer. A side view of PGHS is drawn in panel A and the different
domains are labeled. The EGF-like domains are colored red, the membrane binding domain yellow, and the catalytic domains, blue and gray. Flurbiprofen and
the heme cofactor are colored green and pink, respectively, in the left-hand (gray) monomer. All views are with respect to the postulated plane of the
membrane, which is shown as a dark line. The view from underneath PGHS is drawn in panel B and the four different helices (A–D) of the MBD are labeled.
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of the protein and comparison with other globular heme-containing per-
oxidases lacking the EGF and MBD domains, notably mammalian myeloper-
oxidase (10). The hypothesis was subsequently conﬁrmed by a variety of
photolabeling, mutagenesis (23,25), and ﬂuorescent protein fusion exper-
iments (24).
The hydrophobic substrate, arachidonic acid, is partitioned into the
membrane and, it is assumed, enters the enzyme directly via the MBD. After
cyclooxygenation, the product, PGG2, is expelled from the COX site of
PGHS and then binds to a peroxidase-active site where the ﬁnal conversion
to PGH2 takes place. Differences between PGHS-1 and PGHS-2 that may be
exploited in the design of inhibitors could potentially be in any one of these
steps. We assume here that it is most likely that differences will occur in the
interactions between the drug and the enzyme; hence, we study ﬂurbiprofen
bound to the COX active site of PGHS-1 and -2. However, it is possible that
other important differences may exist—for example, in the mechanism of
entry of the substrate into each isozyme. This has been studied by Molnar
et al. (26) using steered molecular dynamics.
Integration protocol
We will now describe the protocol used to integrate a monomer PGHS with
a phospholipid bilayer. It was decided to integrate monomers rather than
dimers to limit the size the system; however, we expect this approach to
apply to PGHS dimers also. The protocol exploits the force exerted by the
vacuum created when a number of lipids are removed from the bilayer
directly beneath PGHS to integrate the enzyme rapidly into the membrane.
This approach was ﬁrst used by Nina et al. (27) to integrate the MBD into a
small patch of lipids and we extend it here to an entire PGHS monomer. This
has the advantage that we do not need any restraints on the protein and, by
virtue of increased computer processor speeds and improved algorithms, we
were able to evolve our models for 15 ns compared to the 1 ns performed by
Nina et al. (27).
The membrane plug-in to VMD1.8.3 (28) was used to generate a patch of
bilayer comprising 214–234 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphati-
dylcholine (POPC) lipids, POPC being the most common constituent of the
endoplasmic reticulum (29). The protein was oriented such that helices A, B,
and C of the MBD were in the plane of the phospholipid bilayer. Deﬁning
the z axis as perpendicular to the phospholipid bilayer with its origin at the
center of the bilayer (see Fig. 1), the number of lipids within 2 A˚ of the protein
was calculated as a function of z. The center of mass of the protein was then
moved to a z coordinate (48–50 A˚) such that it was in close contact with 17
lipids.
Deciding how many lipids to remove is a packing problem; in principle,
one should remove the number of lipids (11) equivalent to the cross-
sectional area of the MBD to ensure the membrane is minimally perturbed.
This, however, does not allow the enzyme to be positioned very close to
the bilayer as the MBD does not ﬁt well into the cavity produced due to
discrete size effects. An additional six lipids were removed to allow the
MBD to better ﬁt the cavity and we expect the perturbation introduced by
the integration of PGHS into the membrane to dominate any potential
perturbation in the curvature of the membrane due to the removal of these
additional lipids. Any effect is further reduced by using a large patch of
POPC lipids.
Having removed these 17 POPC lipids to create the cavity beneath the
protein, the protein was solvated and then neutralized by adding counterions;
care was taken to ensure no water molecules entered this cavity. The poten-
tial energy of the system was then minimized and the water and side chains
relaxed before the system was thermalized up to physiological temperature
(310 K) over 0.5 ns. During the warming, harmonic restraints in the z di-
rection were applied to selected heavy atoms within the headgroups of the
phospholipids. The magnitude of the restraints was decreased and removed
before a Berendsen barostat was applied to maintain the system at 1 atm
pressure. A Langevin thermostat was used to maintain the temperature at
310 K and production runs were 15 ns long. This duration is typical for
current transmembrane protein simulations (30).
Systems studied
Table 1 lists the four PGHS monomers studied and their respective Protein
Data Bank (PDB) codes (31). The heme group was included but the proteins
were not glycosylated, as it has been shown that this is not necessary for their
function (10).
The ﬂurbiprofen-bound PGHS-2 system (referred to as cPGHS-2) is
typical and contains a PGHS monomer, 1 ﬂurbiprofen molecule, 1 heme
group, 6 sodium cations, 215 POPCmolecules, and 23,193 TIP3Pwater mol-
ecules, with typical dimensions ;80 A˚ 3 80 A˚ 3 150 A˚.
Algorithms
We used NAMD2.5, a parallel classical molecular dynamics algorithm to
minimize, warm, equilibrate, and evolve the dynamics of our system (32).
NAMD has excellent scaling capabilities and therefore allows rapid com-
putation using either regular high performance computing (HPC) or grid
computing resources. For example, using the IA-64 Linux cluster at NCSA
(part of the US TeraGrid—www.teragrid.org), we are able to simulate 1 ns in
6.25 wallclock hours when running on 192 processors. The compute nodes
of the UK National Grid Service (www.ngs.ac.uk) and HPCx (www.hpcx.
ac.uk) yielded comparable performance.
The standard protein and lipid CHARMM27 force ﬁeld was used, which
includes parameters for POPC and heme (33). The unknown bonding pa-
rameters and all the partial charges for ﬂurbiprofen were determined using an
MP2/SBK ab initio approach. SHAKE was used to admit a 2 fs integrator
timestep (34) and the particle-mesh Ewald method was used to compute the
electrostatic forces (35). Conformations were saved every 2–5 ps and van
derWaals interactions were cut off at 12 A˚ with a switching distance of 10 A˚.
Steered molecular dynamics simulations used a spring constant of 0.486 nN/
A˚ and a bead velocity of 53 105 A˚ per timestep. VMD1.8.3 (28) was used
to perform all analysis and to produce the illustrations within this article.
TABLE 1 PGHS systems simulated
Identiﬁer Species Complex PDB structure used Size (atoms)
aPGHS-1 Sheep Apo 1prh (2) 103,683
aPGHS-2 Mouse Apo 5cox (39) 101,815
cPGHS-1 Sheep Flurbiprofen 1eqh (40) 111,022
cPGHS-2 Mouse Flurbiprofen 3pgh (39) 107,353
FIGURE 2 Snapshots of themonomeric PGHS-1 system at different times.
The nitrogen atoms of the choline groups of the POPC lipids are drawn as
blue spheres to allow easy identiﬁcation of the lipid-water interface.
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RESULTS
The aim of the integration protocol is to integrate PGHS into
a phospholipid bilayer to ensure that the environment, and
therefore the dynamics, of the protein is more representative
of that in vivo. Given the assumptions inherent in our com-
putational models and the relatively short timescales that we
can access by MD, we cannot prove deﬁnitively that the pro-
tein has correctly integrated in the bilayer, but we can present
evidence indicating it is very likely to be correctly integrated.
In this section we will describe results that demonstrate
that:
1. The protein becomes well integrated into the bilayer.
2. The protocol is repeatable.
3. PGHS is stable throughout.
4. It is bound to the membrane.
5. PGHS interacts with individual phospholipids in a man-
ner reminiscent of the interactions formed by transmem-
brane proteins.
Integration
Snapshots of cPGHS-1 at different times (see Fig. 2) show
PGHS integrating with the bilayer. A more quantitative mea-
sure of integration is shown in Fig. 3, A–C; here, the atomic
densities, r(z), of the membrane-binding domain (MBD), the
whole enzyme, and the lipid bilayer are averaged over 250 ps
windows and plotted as a function of z, where z is the
distance from the center of the phospholipid bilayer. This
shows that the MBD (and the whole protein) sinks;5 A˚ into
the membrane in the ﬁrst 5 ns with little change in the fol-
lowing 10 ns.
Following the analysis of Deol et al. (36) on transmem-
brane proteins, we deﬁne the number of close contacts, c(t),
between the protein and the lipid bilayer as the number of lipid
atoms within 3.5 A˚ of the protein. This is plotted in Fig. 4 and
the number of lipid atoms in contact with cPGHS-1 increases
from ;50–400. As expected, if we separate the interactions
made between the protein and headgroups and tails of the
lipids, the majority of this increase is due to additional
interactions with lipid tails as the protein sinks into the bilayer
and the lipids rearrange (data not shown). If we assume that a
protein is integrated when a plateau in c(t) is attained, then this
metric and our previous analyses indicate that cPGHS-1 is
integrated (and therefore equilibrated) after 5 ns.
FIGURE 3 The atomic densities, r(z), as a function of z for the membrane binding domain (solid line), the whole enzyme (dotted line), and the phospholipid
bilayer (dashed line) for both PGHS-1 and PGHS-2 show the integration of the protein into the bilayer. Panels A–C and D and E show the progressive
integration of PGHS-1 and PGHS-2, respectively, at t ¼ 0, t ¼ 5 ns, and t ¼ 14.75 ns. The value r(z) is averaged over a 250 ps window and is measured in
kg m3.
FIGURE 4 The number of close contacts as a function of time, c(t), for
each of the four systems studied (see Table 1), reaches a plateau after;5 ns.
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Repeatability
We expect PGHS to integrate into the membrane indepen-
dently of the initial conditions. If we assume that the force
exerted due to the cavity dominates any differences between
the two isozymes or between the apo and ﬂurbiprofen-bound
forms, then we also expect different isozymes of PGHS to
integrate in the same way. The repeatability of the protocol is
tested in two ways: 1), the integration of the four different
PGHS systems given in Table 1 is compared; and 2), a mod-
iﬁed protocol, with alternating restraints, is compared to the
unmodiﬁed protocol for aPGHS-1.
Examining c(t) for all four systems indicates that each
forms similar numbers of close contacts with lipids and that
each isozyme is integrated after ;5 ns (Fig. 4). The distri-
butions of atomic densities, r(z) for cPGHS-1 and cPGHS-2
are compared in Fig. 3 and are also similar, although r(z)
suggests that the MBD of cPGHS-2 does not appear as well
integrated after 15 ns as cPGHS-1. This is not supported by
examining c(t).
To further check the sensitivity of the protocol, an addi-
tional integration simulation was run with the backbone of
aPGHS-1 and the headgroups of the phospholipids alterna-
tively restrained for 0.1–0.5 ns by an harmonic potential. The
distributions of the densities for this restrained simulation are
shown in Fig. 5; as expected, the MBD is less well integrated
after 5 ns; however, after 15 ns, the MBD is entirely within
the bilayer. The number of close contacts, c(t), is plotted in
Fig. 6 and is similar for both the restrained and unrestrained
simulations. The differences in c(t) between the restrained
and unrestrained simulations are within the variation seen for
different systems in Fig. 4. The protocol is therefore re-
peatable; it is moderately insensitive to changes and different
PGHS systems are integrated to the same degree.
Stability
The rapid integration of PGHS into the phospholipid bilayer
might be expected to signiﬁcantly perturb the conformation
of the protein. Again, we assume that the differences in se-
quence and structure between the four systems are domi-
nated by the force exerted by the cavity. Fig. 7 plots the Ca
RMSD for the four systems against their respective x-ray
crystallographic structures (see Table 1). After an initial
increase, the RMSD for each system ﬂuctuates with a max-
imum of 3.0 A˚ for aPGHS-1 and a minimum of 1.8 A˚ for
FIGURE 5 Atomic densities, r(z), as a function of z for the MBD (solid
line), the whole enzyme (dotted line), and the phospholipid bilayer (dashed
line) for the restrained integration of aPGHS-1. Densities are plotted at
different times: t ¼ 0 (panel A), t ¼ 5 ns (panel B), and t ¼ 14.75 ns (panel
C). The value r(z) is averaged over a 250 ps window and is measured in
kg m3.
FIGURE 6 The number of close contacts as a function of time, c(t), for
the restrained integration of apo PGHS-1. The restrained and unrestrained
simulation are drawn with a solid line and a broken line, respectively.
FIGURE 7 The root mean-square devia-
tions as a function of time for each of the four
systems studied. The differences between the
RMSDs for the different systems shown in
panel A are reduced by ﬁtting on each domain
separately (B), thereby removing any inter-
domain motion. Either RMSDmeasure for all
four systems is ,3 A˚ throughout and there-
fore their structures remain similar to their
x-ray crystallographic structures.
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cPGHS-1. This range of RMSD values for a protein of this
size indicates that the protein is stable throughout the simu-
lations and therefore also during the integration protocol. To
assess how much of the difference in behavior between
systems was due to interdomain motion, the mean-square
deviation of each domain was calculated and then combined
to give an RMSD of the whole protein, which ignores dif-
ferences in domain orientation (RMSD9). This is plotted in
Fig. 7 B and all four systems have more similar values of
RMSD9 (1.5–2.5 A˚) than RMSD, indicating that some of the
structural changes are due to interdomain motions.
To verify that the dynamics of a PGHS monomer is not
likely to be signiﬁcantly different to the dimer, the average
structures were compared to the x-ray crystallographic struc-
tures and the RMSD for each residue was calculated.
Examining the RMSD of the surface residues of the proteins
indicates that the dimer interface, with the exception of a
short a-helix (residues 363–370), has similar RMSD values
to the remainder of the surface residues (data not shown).
It is usual to assume that a protein has equilibrated when
a plateau in RMSD is attained. This implies that all four
systems have equilibrated after 2.5 ns. This is half the time
estimated for the proteins to integrate with the phospholipid
bilayer and is consistent with a rapid sinking of the protein
into the bilayer followed by a rearrangement of the lipids
around the MBD.
Binding
To test whether the protein is bound to the phospholipid bi-
layer after the integration process (as deﬁned by the ﬁrst 5 ns
of each production trajectory), we applied a force to the
aPGHS-1 system to try to unbind it. We used the steered
molecular dynamics functionality of NAMD (37). A bead is
connected by a spring to the center of mass of the protein, then
pulled with a constant velocity in the z direction and the force
in the spring recorded. To control for the viscous forces
experienced by the protein due to the water, we repeated the
experiment for a simple solvated aPGHS-1 system. Finally,
both systems were rerun from a different initial conformation.
Fig. 8 shows that the force required to move the membrane-
bound aPGHS-1 protein a ﬁxed distance was signiﬁcantly
higher than the force required to move the solvated aPGHS-1
protein. This implies that the aPGHS-1 protein has formed
interactions with the bilayer preventing its free movement.
Examining the trajectories shows that the membrane-bound
protein deforms under the tension and the MBD remains at-
tached to the bilayer for some time, partially deforming the
bilayer itself before being pulled free (Fig. 9). In the next sec-
tion we will study the interactions the MBD forms with the
phospholipid bilayer.
FIGURE 8 The force applied to PGHS for the bound (dashed lines)
systems and the unbound (solid lines) systems, showing how a signiﬁcantly
larger force is required to move the bound system the same distance as the
unbound system. Due to the ﬂuctuations in the force, each bound and
unbound case was repeated twice.
FIGURE 9 Snapshots from a steered molecular dynamics simulation as
PGHS is pulled free of the phospholipid bilayer at three different values of
the displacement, d. Note the deformation of the lipid bilayer.
FIGURE 10 Multiple-alignment of PGHS-1 and
PGHS-2 primary sequences (MBD region only).
Note that the ﬁrst two sequences are those with x-ray
crystallographic structures and are those studied in
this article. Basic residues (W,Y) and aromatic am-
phipathic residues (R,K) are colored purple and
yellow, respectively.
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Protein-lipid interactions
Although the sequence conservation between PGHS-1 and -2
is 60–65%, it is only 38% within the membrane binding
domain (MBD) (23). Despite this there are many conserved
or semiconserved residues (see Fig. 10), notably amphipathic
aromatic (Tyr, Trp) and basic residues (Arg, Lys). For a more
complete sequence alignment, see the review by Simmons
et al. (11). These residues are found on the helices as well as
within the interior of the MBD and on the surface (Fig. 11).
The high degree of conservation in a region of overall low
homology implies that these residues have a speciﬁc function.
Conserved bands of aromatic amphipathic and basic res-
idues are observed for many different transmembrane proteins
(38); these residues form stabilizing interactions with the
phospholipid bilayer. For example, so-called snorkeling inter-
actions between basic residues and the phosphate groups have
beenobservedduring computational studies ofKcsAandOmpA
(36). In our simulations, both basic and aromatic residues were
observed forming close interactions with phospholipids after the
integration of the protein into the phospholipid bilayer. We will
concentrate on the hydrogen bonds formed by the basic residues
since these are more easily quantiﬁed.
One example of an interaction between a basic residue and
one or two phospholipids from each of the cPGHS-1 and
cPGHS-2 simulations is illustrated in Figs. 12 and 13. Argi-
nine is potentially very promiscuous as its guanidinium group
allows it to form several hydrogen bonds (or a single ionic
interaction) with several oxygens of one or more phosphate
groups. For this example, the hydrogen bonds formed with
Arg-114 persist for longer (up to 10 ns) than the hydrogen
bond formed with Lys-114 for cPGHS-2. Finally, as we
would expect, the hydrogen bonds occasionally swap from
one oxygen atom on the phosphate group to another.
It is difﬁcult to draw general conclusions from individual
interactions, so we seek more global measures now. The total
number of hydrogen bonds, h(t), formed between the protein
and the lipids is plotted in Fig. 14. With the exception of
cPGHS-2, the number of hydrogen bonds formed increases in
the ﬁrst 5 ns to 5–10. For both isozymes, the basic residues
make up the majority of the hydrogen bonds formed between
the MBD and the phospholipid bilayer; however, there are
differences due to the lack of arginines on theMBDof PGHS-
1 (Figs. 10 and 11).
It has been suggested in the literature that the PGHS iso-
zymes have signiﬁcantly different free energies of binding to
membranes (23). As we have seen, the guanidinium group of
arginine allows it to form multiple simultaneous hydrogen
bonds and therefore the substitution of arginines by lysines
FIGURE 11 The distribution of basic and aromatic amphipathic residues
on the membrane binding domain (MBD). oPGHS-1 is on the left, mPGHS-
2 is on the right. Basic residues (Arg, Lys) are shown in blue and aromatic
amphipathic residues (Trp, Tyr) are shown in yellow. Aromatic and amphi-
pathic residues have been shown to interact with individual phospholipids
and stabilize transmembrane proteins in membranes.
FIGURE 12 An example of a typical interaction
between an arginine of cPGHS-1 and several phos-
pholipids. Panel A shows Arg-114 of cPGHS-1
forming four hydrogen bonds, labeled i–iv, with two
separate POPC lipids. The hydrogen-bonding dis-
tances for these bonds are plotted in panels B and C.
The bonds persist for up to 10 ns and the guanid-
inium group bonds to different oxygens on the
phospholipids. Hydrogen bonds are indicated by a
dashed line and each is labeled. The lipids are drawn
without hydrogens for clarity and only the MBD is
drawn and the different helices are labeled.
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on theMBD of PGHS-2 could explain the difference between
the binding free energies.
In all x-ray crystallographic structures, helixB is observed to
lie slightly above helices A and C relative to the plane of the
membrane (Fig. 1). In a previous study of theMBD,Nina et al.
(27) calculated the free energy of solvation of the helices A–D
using a mean ﬁeld approach. Their results suggested that helix
B should lie in the sameplane as helicesA andC and its reported
position was therefore taken to be an artifact of the extraction
and crystallization process. Helix B, however, remains above
helices A and C in all our simulations (data not shown).
We suggest that this is because, unlike helicesA andC, helix
B has no basic residues that can form stabilizing snorkeling
interactions. As a result, helix B integrates less deeply into the
phospholipid bilayer than helix A or C. An atomistic effect of
this nature would not be detected by a mean ﬁeld approach;
however, there is a histidine residue on helix B that we chose
to make neutral in our simulations. Were this residue to be
protonated, then one might expect helix B to form hydrogen
bonds with a lipid phosphate group, become more integrated
into the bilayer and therefore be drawn toward the plane of
helicesA andC. This could be testedby further simulations.We
note that there is some limited evidence from mutagenesis
experiments to support the hypothesis that helix B binds less
strongly to the phospholipid bilayer than its neighbors, al-
though this is not conclusive (23).
CONCLUSIONS
Monotopic proteins are an interesting and important class of
proteins thatmerit investigation. In commonwith other integral
membrane proteins, determining their structure and studying
their function is difﬁcult. Computational approaches, such
as classical molecular dynamics, allow the scientist to gain
insight into the behavior ofmonotopic proteins and from these
studies suggest hypotheses that may be tested by experiment.
Although some aspects of how PGHS binds to the mem-
brane are known, the precise orientation of the protein and
the depth to which it sinks in the membrane is unknown. We
have described a protocol to rapidly integrate a PGHS mono-
mer into a phospholipid bilayer. The force exerted by the
cavity produced when several lipids are removed from di-
rectly beneath the monomer is exploited to pull the protein into
the membrane. This protocol is an extension of the earlier
work carried out by Nina et al. (27). It would be interesting
to examine whether this protocol could be applied to the
integration of squalene-hopene cyclase, as it appears to bind
to membranes in a similar manner to PGHS (3).
FIGURE 13 An example of a typical interaction
between a lysine of cPGHS-2 and a phospholipid.
Panel A shows Lys-114 of cPGHS-1 forming a
single hydrogen bond, labeled (v), with the phos-
phate group of a POPC lipid. This hydrogen bond
is intermittent and persists for no longer than 2 ns
(panel B). The lipids are drawn without hydrogens
for clarity and only the MBD is drawn and the
different helices are labeled.
FIGURE 14 The total number, h(t), of hydrogen
bonds between the MBD and the lipid bilayer (solid
line) for the four PGHS systems studied (see Table
1). The cumulative number of hydrogen bonds
involving arginine (dashed line) and lysine (dotted
line) are also plotted. A hydrogen bond is assumed
to have formed if the distance between donor and
acceptor is ,3.5 A˚ and the deviation is ,30. The
total number of hydrogen bonds for apo-PGHS-
1 and -2 is plotted in panels A and B, and for h(t) for
ﬂurbiprofen-bound PGHS-1 and -2 is plotted in
panels C and D.
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Our protocol was applied to both apo and ﬂurbiprofen-
bound PGHS-1 and PGHS-2 systems. For all four systems,
the PGHS monomer sinks by ;5 A˚ into the bilayer and the
number of close contacts made between the monomer and
lipids increases signiﬁcantly during the ﬁrst 5 ns. The proto-
col therefore integrates the PGHS monomer with the phos-
pholipid bilayer within the ﬁrst 5 ns and is repeatable. The
monomer is also stable throughout all our simulations. To
demonstrate that, once integrated, the protein is bound, we
used steered molecular dynamics to apply a force perpen-
dicular to the plane of the membrane.
The most compelling evidence that the monomer is
located at the correct depth in the bilayer is the formation of
stabilizing snorkeling interactions between the conserved
basic residues of the membrane binding domain and the
phosphate groups of the lipids. Analogous interactions have
been observed in simulations of transmembrane proteins
(36). A series of mutagenesis experiments on the conserved
basic residues of the membrane binding domain would help
test our hypothesis that their function is to form stabilizing
interactions. None of the mutagenesis experiments per-
formed on the membrane-binding domain to date has inves-
tigated the role of the basic residues (23).
Depending on the motion, the relaxation times of phos-
pholipids in bilayers can be much larger than the timescales
we have studied here. This makes it more difﬁcult to assess
whether the entire system is equilibrated, particularly whether
the membrane has adapted to the presence of the monotopic
protein. We assume, however, that following the rapid inte-
gration of the PGHS monomers into the bilayer in the ﬁrst 5
ns, the environment surrounding the enzyme more closely
mimics that in vivo. The integration of PGHS with a phos-
pholipid bilayer is the ﬁrst step in assessing the dynamical
differences between PGHS-1 and PGHS-2. In future publi-
cations we will report on the differences that we observe for
both monomers and dimers, the hypotheses that are subse-
quently generated, and possible experimental tests of our
theoretical ﬁndings.
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